Chilean Pediatric Type 1 Diabetes Incidence Doubled Since 2007

The management of pediatric type 1 diabetes has evolved significantly with the integration of continuous glucose monitoring and insulin pump technologies, though these devices are associated with dermatologic complications such as contact dermatitis and lipodystrophies (localized changes in fat tissue distribution) [1]. Despite these advancements, acute complications such as diabetic ketoacidosis (a life-threatening state of metabolic exhaustion characterized by hyperglycemia and acidosis) remain a persistent threat to patient safety [2, 3]. Recent meta-analyses involving over 150,000 children indicate that the COVID-19 pandemic significantly altered disease presentation, with the risk of diabetic ketoacidosis increasing by 35% to 68% compared to pre-pandemic levels [4, 5]. Clinicians have observed a particularly sharp rise in severe metabolic decompensation at initial diagnosis, with one analysis of 124,597 patients showing a relative risk of 1.41 (95% CI 1.19, 1.67) for ketoacidosis among newly diagnosed cases [3]. Furthermore, the odds of requiring intensive care unit admission rose significantly (OR 1.90; 95% CI 1.60-2.26) during this period [4]. A new population-based analysis now provides a multi-year perspective on how these epidemiological shifts manifested within a national healthcare system.